E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute symptomatic deep vein thrombosis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 7.0 |
E.1.2 | Classification code | 10051055 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objectives of this Phase II dose finding trial are to assess the dose-effect relationship of once-daily BAY 59-7939 in the treatment of patients with confirmed acute symptomatic deep vein thrombosis, using the combination of (LMW) heparin and VKA as comparator. The objective is also to determine the optimum once daily dose of BAY 59-7939 for use in phase III studies. Pharmacokinetic and pharmacodynamic parameters (incl, activated partial thrombin time (aPTT), INR, Factor Xa activity and Heptest) will also be assessed.
|
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
- Patients with confirmed acute symptomatic deep vein thrombosis i.e. proximal or extensive calf-vein thrombisis involving at least the upper third part of the calf veins, without concomitant symptomatic PE - Patients who have signed an informed consent form for participation prior to study entry |
|
E.4 | Principal exclusion criteria |
- Legal lower age limitations (country specific) - Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT - Other indication for VKA than PE/DVT - More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW) heparin or more than a single dose of VKA prior to randomization - Participation in another pharmacotherapeutic study within the prior 30 days - Creatinine clearance < 30 mL/min, impaired liver function (transaminases > 2X ULN), or bacterial endocarditis - Life expectancy < 3 months - Active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin - Uncontrolled hypertension: systolic blood pressure > 200 mmHg and diastolic blood pressure > 110 mmHg - Pregnancy or childbearing potential without proper contraceptive measures . - Any other contraindication listed in the labeling of warfarin, acenocumarol, phenprocoumon, fluidione, UFH, enoxaparin, or tinzaparin - Systemic treatment with azole compounds or other strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazol, itraconazol, HIV protease inhibitors) within 4 days prior to randomization and during the study
Prior and concomitant medication Medication prior to randomization
Therapeutic dosages of (LMW) heparin are allowed up to a maximum of 36 hours prior to randomization. The duration of prophilactic dosages of (LWM) heparin is not restricted. A single pre-randomization starting dose of VKA is also allowed.
Concomitant medication Non-steroid anti-inflammatory drugs (NSAIDs) and antiplatelet agents are discouraged. However if indicated, aspirin up to a dosage of 100 mg/day as well as clopidogrel (75 mg/day) are allowed. Use of systemic treatment with azole compounds or other strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazol, itraconazol, HIV protease inhibitors) within 4 days prior to randomization and during the study are not allowed |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint will be the composite of syntomatic recurrent DVT or syntomatic fatal and non-fatal PE at 12 weeks and deterioration in thrombotic burden, as assessed by CUS and PLS, at basekine and at 12 weeks..
Secondary efficacy endpoints : - The separate components of the primary efficacy outcome at 12 weeks
The following definitions are applied by the CIAC to confirm a suspected episode of symptomatic recurrent PE/DVT:
1. Suspected PE with one of the following findings: - a (new) intraluminal filling defect in (sub)segmental or more proximal branches on spiral CT scan - a (new) intraluminal filling defect or an extension of an existing defect or a new sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram - a (new) perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS) or 2. Suspected recurrent DVT with one of the following findings:
- abnormal CUS where compression had been normal or, if non-compressible at screening, a substantial increase (4 mm or more) in diameter of the thrombus during full compression - an extension of an intraluminal filling defect, or a new intraluminal filling defect or an extension of non-visualization of veins in the presence of a sudden cut-off on venography or 3. Fatal PE based on autopsy or 4. Death which cannot be attributed to a documented cause and for which PE/DVT can not be ruled out (unexplained death)
Safety Variables
The principal safety outcome is: - clinically relevant bleeding (i.e. major bleeding and clinically relevant non-major bleeding) within 12 weeks Additional safety outcomes are: - the separate components of the safety outcome at week 12 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Double blind within BAY treatment groups, assessor blind for all groups |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 10 |